News
Category: DIAN-TU Announcement
Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)
The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for...
Update on the DIAN-TU-002 Primary Prevention Trial
20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...
Update on the DIAN-TU-001 Open Label Extension and DIAN-TU-002 Primary Prevention Trials with Gantenerumab (Roche/Genentech)
The statement below is in response to the 14 November 2022 announcement regarding the results from the GRADUATE I and...
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...
New Alzheimer’s prevention trial in young people
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
$11.5 million commitment supports new Alzheimer’s prevention clinical trial
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
International Alzheimer’s clinical trial to test two drugs in combination
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - NOV 8 2021
International Alzheimer’s clinical trial to test tau drugs
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - MAR 15 2021 Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a...
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates